Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizo ...

While many people take supplements for brain health, the research supporting supplemental nutrients' effects on brain health ...

Nootropics are touted as “smart drugs” meant to improve cognitive performance. But there’s a lot we still don’t know about ...

The condition is most commonly diagnosed in people in their 70s, but you can take steps before then to make your brain more ...

Learn all about the best Delta 9 THC gummies that can help you relax and boost your sleep quality, while some featured ...

In a world grappling with obesity and chronic disease, GLP-1 drugs like Ozempic are emerging as transformative game-changers. Initially designed for diabetes, these medications now promise ...

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation.

AXS-05 reduced Alzheimer’s severity and showed a 3.6-fold lower relapse risk in ACCORD-2. Long-term safety trials showed no increase in falls, sedation, or cognitive decline for AXS-05.

US CNS specialist Axsome Therapeutics (Nasdaq: AXSM) yesterday announced the completion of its Phase III clinical program evaluating AXS-05 (dextromethorphan-bupropion), a novel, oral, investigational ...

The US market looks expensive, so investors may be wondering which stocks to buy now against this backdrop. Regardless of where the markets are headed, investors may want to own companies that ...

The FDA approves an injectable Opdivo cancer drug; Axsome seeks approval for an Alzheimer's drug amid mixed results; Hain ...

The New York-based biopharmaceutical company ran two studies for the treatment of agitation – a common symptom of Alzheimer’s disease – using its AXS-05 drug.